| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000021973 |
| Receipt No. | R000025329 |
| Official scientific title of the study | Multicenter prospective study on the usefulness and safety of edoxaban replacement before the endoscopic therapy with high-risk bleeding group during anticoagulant therapy with warfarin |
| Date of disclosure of the study information | 2016/04/18 |
| Last modified on | 2018/10/20 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Multicenter prospective study on the usefulness and safety of edoxaban replacement before the endoscopic therapy with high-risk bleeding group during anticoagulant therapy with warfarin | |
| Title of the study (Brief title) | Disestive disorders requiring the endoscopic therapy in high-risk bleeding group | |
| Region |
|
|
| Condition | |||
| Condition | Disestive disorders requiring the endoscopic therapy in high-risk bleeding group | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To verify that usefulness and safety of the endoscopic therapy by edoxaban replacement versus heparin replacement in high-risk bleeding group from anticoagulant therapy with warfarin |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | The frequency of bleeding for 2 weeks after the endoscopic therapy |
| Key secondary outcomes | The frequency of thrombotic events |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | edoxaban replacement in high-risk bleeding group from anticoagulant therapy with warfarin.
|
|
| Interventions/Control_2 | heparin replacement in high-risk bleeding group from anticoagulant therapy with warfarin | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients in the anticoagulation therapy with warfarin is needed the endoscopic therapy in high-risk bleeding group, and meet following criteria:
1)The patient written consent has been obtained 2)The patient over the age of 20 3) The patient's platelet 50000 / mm3 or more |
|||
| Key exclusion criteria | 1) The patient who has taken warfarin after heart valve replacement
2) The patient with severe comorbidity 3) The patient cannot be obtained with informed consent 4) The patient prohibited the participant of this study by their research investigator |
|||
| Target sample size | 180 | |||
| Research contact person | |
| Name of lead principal investigator | Shinichi Hashimoto |
| Organization | Kagoshima University |
| Division name | Digestive and Lifestyle Diseases |
| Address | 8-35-1 Sakuragaoka, Kagoshima |
| TEL | 0992755326 |
| kumdsh@m.kufm.kagoshima-u.ac.jp | |
| Public contact | |
| Name of contact person | Shinichi Hashimoto |
| Organization | Kagoshima University |
| Division name | Digestive and Lifestyle Diseases |
| Address | 8-35-1 Sakuragaoka, Kagoshima |
| TEL | 0992755326 |
| Homepage URL | |
| kumdsh@m.kufm.kagoshima-u.ac.jp | |
| Sponsor | |
| Institute | Digestive and Lifestyle Diseases, Kagoshima University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Digestive and Lifestyle Diseases, Kagoshima University |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025329 |